nach oben

International Urology and Nephrology

Erschienen in:

24.11.2018 | Urology - Original Paper

The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats

verfasst von: Honglin Ding, Peng Zhang, Ning Li, Yili Liu, Ping Wang

Erschienen in: International Urology and Nephrology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To demonstrate that phosphodiesterase type 4 (PDE4) inhibitors could potentially treat diabetic bladder dysfunction (DBD) through modulation of the systemic inflammatory response.

Methods

In this 6-week study, 60 female Sprague–Dawley rats were divided into three groups: (i) vehicle-treated control rats; (ii) vehicle-treated streptozocin (STZ)-injected rats; and (iii) roflumilast-treated STZ-injected rats. Oral roflumilast (5 mg/kg/day) was administered during the last 4 weeks of STZ injection to induce diabetes in the test group. At 6 weeks, a urodynamic study was performed in each group. The expression of nuclear factor kappa B (NF-κB), tumor necrosis factor-alpha (TNF-α), interleukin (IL)-6, and IL-1β in detrusor smooth muscle (DSM) was analyzed using quantitative reverse transcription-polymerase chain reaction and Western blotting.

Results

A significant decrease in bodyweight and significant increases in bladder weight and blood glucose level were observed in the diabetic rats and were not ameliorated by roflumilast treatment. Cystometry showed the increased bladder capacity, voiding volume, residual urine volume, and voiding interval in the diabetic rats and the prevention of these changes by roflumilast. These changes were accompanied by significantly enhanced expression of NF-κB, TNF-α, IL-6, and IL-1β in DSM tissue from diabetic rats. Furthermore, roflumilast attenuated the expression of inflammatory factors in DSM tissue.

Conclusions

Oral treatment with roflumilast in diabetic rats improves bladder function and inhibits the expression of inflammatory factors in DSM tissue, indicating that PDE4 is a potential therapeutic target for DBD.

Daneshgari F et al (2009) Diabetic bladder dysfunction: current translational knowledge. J Urol 182(6):18–26

Lin CC et al (2013) Time trend analysis of the prevalence and incidence of diagnosed type 2 diabetes among adults in Taiwan from 2000 to 2007: a population-based study. BMC Public Health 13(1):318CrossRef

Arrellano-Valdez F et al (2014) A comprehensive review of urologic complications in patients with diabetes. Springerplus 3(1):549CrossRef

Wang CC et al (2009) Diabetes-induced alternations in biomechanical properties of urinary bladder wall in rats. Urology 73(4):911–915CrossRef

Karoli R et al (2014) A study of bladder dysfunction in women with type 2 diabetes mellitus. Indian J Endocrinol Metab 18(4):552CrossRef

Ueda T, Yoshimura N, Yoshida O (1997) Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J Urol 157(2):580–584CrossRef

Staskin DR, Robinson D (2009) Oxybutynin chloride topical gel: a new formulation of an established antimuscarinic therapy for overactive bladder. Expert Opin Pharmacother 10(18):3103–3111CrossRef

Ren LM et al (2013) Berberine improves neurogenic contractile response of bladder detrusor muscle in streptozotocin-induced diabetic rats. J Ethnopharmacol 150(3):1128–1136CrossRef

Kawasaki N et al (2012) Obesity-induced endoplasmic reticulum stress causes chronic inflammation in adipose tissue. Sci Rep 2:799CrossRef

10.

Haldar S et al (2015) Inflammation and pyroptosis mediate muscle expansion in an interleukin-1beta (IL-1beta)-dependent manner. J Biol Chem 290(10):6574–6583CrossRef

11.

Bouchelouche K et al (2006) Human detrusor smooth muscle cells release interleukin-6, interleukin-8, and RANTES in response to proinflammatory cytokines interleukin-1β and tumor necrosis factor-α. Urology 67(1):214–219CrossRef

12.

Wang Z et al (2012) Inhibition of TNF-alpha improves the bladder dysfunction that is associated with type 2 diabetes. Diabetes 61(8):2134–2145CrossRef

13.

Ndisang JF (2010) Role of heme oxygenase in inflammation, insulin-signalling, diabetes and obesity. Mediat Inflamm 2010:359732

14.

Ding H et al (2017) Treatment of obesity-associated overactive bladder by the phosphodiesterase type-4 inhibitor roflumilast. Int Urol Nephrol 49(10):1723–1730CrossRef

15.

Schafer PH et al (2016) Phosphodiesterase 4 in inflammatory diseases: effects of apremilast in psoriatic blood and in dermal myofibroblasts through the PDE4/CD271 complex. Cell Signal 28(7):753–763CrossRef

16.

Sturton G, Fitzgerald M (2002) Phosphodiesterase 4 inhibitors for the treatment of COPD. Chest 121(5 Suppl):192S–196SCrossRef

17.

Daneshgari F, Liu G, Imrey PB (2006) Time dependent changes in diabetic cystopathy in rats include compensated and decompensated bladder function. J Urol 176(1):380–386CrossRef

18.

Li N et al (2016) Partial bladder outlet obstruction is associated with decreased expression and function of the small-conductance Ca²⁺-activated K⁺ channel in guinea pig detrusor smooth muscle. Int Urol Nephrol 49(1):17–26PubMed

19.

Li N et al (2017) Expression and function of the small-conductance Ca²⁺-activated K⁺ channel is decreased in urinary bladder smooth muscle cells from female guinea pig with partial bladder outlet obstruction. Int Urol Nephrol 49(7):1147–1155CrossRef

20.

Durden E et al (2018) The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States. Neurourol Urodyn. https://doi.org/10.1002/nau.23513 CrossRefPubMed

21.

Wang Y et al (2011) Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Neurourol Urodyn 30(8):1448–1455CrossRef

22.

Xu D et al (2017) Prevalence of overactive bladder and its impact on quality of life in 1025 patients with type 2 diabetes in mainland China. J Diabetes Complicat 31(8):1254–1258CrossRef

23.

Bansal R et al (2011) Urodynamic profile of diabetic patients with lower urinary tract symptoms: association of diabetic cystopathy with autonomic and peripheral neuropathy. Urology 77(3):699–705CrossRef

24.

Oger S et al (2007) Relaxation of phasic contractile activity of human detrusor strips by cyclic nucleotide phosphodiesterase type 4 inhibition. Eur Urol 51(3):772CrossRef

25.

Nirmal J et al (2014) Functional and molecular characterization of hyposensitive underactive bladder tissue and urine in streptozotocin-induced diabetic rat. PLoS ONE 9(7):e102644CrossRef

26.

Yoshizawa T et al (2018) Concomitant alteration in number and affinity of P₂X and muscarinic receptors are associated with bladder dysfunction in early stage of diabetic rats. Int Urol Nephrol 50(3):451–458CrossRef

27.

Sakakibara R et al (2013) Neurology and the bladder: how to assess and manage neurogenic bladder dysfunction. With particular references to neural control of micturition. Brain Nerve 53(3):181–190

28.

Liu G, Daneshgari F (2005) Alterations in neurogenically mediated contractile responses of urinary bladder in rats with diabetes. Am J Physiol Ren Physiol 288(6):F1220CrossRef

29.

Mustafa S, Ismael HN (2014) Reactivity of diabetic urinary bladder to the cholinesterase inhibitor neostigmine. Urology 84(6):1549.e1–1549.e5CrossRef

30.

Yang J et al (2012) The size of large adipose cells is a predictor of insulin resistance in first-degree relatives of type 2 diabetic patients. Obesity 20(5):932–938CrossRef

31.

Fathollahi A, Daneshgari F, Hannamitchell AT (2015) Effect of polyuria on bladder function in diabetics versus non-diabetics: an article review. Curr Urol 8(3):119CrossRef

32.

Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132(6):2169–2180CrossRef

33.

Murdolo G et al (2011) Inflammatory adipokines, high molecular weight adiponectin, and insulin resistance: a population-based survey in prepubertal schoolchildren. PLoS ONE 6(2):e17264CrossRef

34.

Kralisch S et al (2008) Secretory products from human adipocytes impair endothelial function via nuclear factor kappaB. Atherosclerosis 196(2):523CrossRef

35.

Rohla M, Weiss TW (2014) Adipose tissue, inflammation and atherosclerosis. Clin Lipidol 9(1):71–81CrossRef

36.

Donath MY et al (2008) Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31(Suppl 2):S161–164CrossRef

37.

Yoon J, Ryoo S (2013) Arginase inhibition reduces interleukin-1β-stimulated vascular smooth muscle cell proliferation by increasing nitric oxide synthase-dependent nitric oxide production. Biochem Biophys Res Commun 435(3):428–433CrossRef

38.

Conti M et al (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278(8):5493–5496CrossRef

39.

El-Ashmawy NE et al (2018) Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP. Int Immunopharmacol 56:36–42CrossRef

40.

Buenestado A et al (2012) Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol 165(6):1877–1890CrossRef

Titel: The phosphodiesterase type 4 inhibitor roflumilast suppresses inflammation to improve diabetic bladder dysfunction rats
verfasst von: Honglin Ding
Peng Zhang
Ning Li
Yili Liu
Ping Wang
Publikationsdatum: 24.11.2018
Verlag: Springer Netherlands
Erschienen in: International Urology and Nephrology / Ausgabe 2/2019
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI: https://doi.org/10.1007/s11255-018-2038-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Case report of inguinal metastasis of epididymal malignant mesothelioma

The effects of oxytocin on penile tissues in experimental priapism model in rats

Current epidemiology and practice patterns in prevention and treatment of PD-related infections in Poland

Correction to: Disparities in early mortality among chronic kidney disease patients who transition to peritoneal dialysis and hemodialysis with and without catheters

Evaluating the associations between urinary excretion of magnesium and that of other components in calcium stone-forming patients